CENTRAL TRUST Co Has $168,000 Position in Edwards Lifesciences Co. (NYSE:EW)

CENTRAL TRUST Co trimmed its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 34.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,553 shares of the medical research company’s stock after selling 1,355 shares during the quarter. CENTRAL TRUST Co’s holdings in Edwards Lifesciences were worth $168,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Brookstone Capital Management boosted its stake in shares of Edwards Lifesciences by 3.2% during the first quarter. Brookstone Capital Management now owns 12,275 shares of the medical research company’s stock valued at $1,173,000 after purchasing an additional 383 shares in the last quarter. Aviance Capital Partners LLC boosted its position in Edwards Lifesciences by 61.8% during the 1st quarter. Aviance Capital Partners LLC now owns 7,194 shares of the medical research company’s stock worth $687,000 after buying an additional 2,748 shares during the period. Miracle Mile Advisors LLC grew its holdings in Edwards Lifesciences by 16.1% during the 1st quarter. Miracle Mile Advisors LLC now owns 10,878 shares of the medical research company’s stock worth $1,040,000 after acquiring an additional 1,507 shares during the last quarter. Hexagon Capital Partners LLC increased its position in Edwards Lifesciences by 33.4% in the 1st quarter. Hexagon Capital Partners LLC now owns 703 shares of the medical research company’s stock valued at $67,000 after acquiring an additional 176 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its stake in shares of Edwards Lifesciences by 4.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 330,711 shares of the medical research company’s stock valued at $31,603,000 after acquiring an additional 14,087 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on EW. Oppenheimer restated an “outperform” rating and issued a $90.00 price objective on shares of Edwards Lifesciences in a report on Thursday, September 12th. Morgan Stanley restated an “equal weight” rating and set a $70.00 price objective on shares of Edwards Lifesciences in a research report on Friday, October 11th. Robert W. Baird cut their price objective on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research note on Friday. The Goldman Sachs Group decreased their target price on shares of Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating for the company in a research report on Friday, July 26th. Finally, Deutsche Bank Aktiengesellschaft dropped their price target on shares of Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, July 25th. Fifteen research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $75.67.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $69.38 on Monday. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. The firm has a fifty day simple moving average of $68.09 and a two-hundred day simple moving average of $78.30. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The firm has a market capitalization of $41.79 billion, a PE ratio of 28.55, a price-to-earnings-growth ratio of 3.00 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same period in the previous year, the firm posted $0.59 earnings per share. The firm’s revenue for the quarter was up 8.9% on a year-over-year basis. Analysts forecast that Edwards Lifesciences Co. will post 2.61 EPS for the current fiscal year.

Insider Activity

In related news, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now owns 29,333 shares in the company, valued at approximately $2,051,843.35. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the transaction, the vice president now directly owns 29,333 shares of the company’s stock, valued at $2,051,843.35. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total transaction of $333,850.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,133,916.72. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 16,250 shares of company stock worth $1,099,238 over the last 90 days. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.